In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant

Gupta, Arpit; Malhotra, Yogangi; Patil, Uday; Muradas, Ana R.; Lee, William T.; Krammer, Florian; Amanat, Fatima; Clare, Camille A.; Vinod, Suja; Ghaly, Emad

doi:10.1055/s-0040-1715177

Cited by 10 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correia and colleagues showed that IgG and IgM in a newborn followed shortly (15 days) after the onset of a late term congenital infection [ 52 ]. Similar findings were also noted after another putative vertical transmission [ 146 ]. During the first trimester infections, maternal SARS-CoV-2 antibody was found among some women but not consistently so [ 18 ].…”

Section: Maternal Infection With Sars-cov-2supporting

confidence: 89%

“…Gupta and colleagues found evidence of virus acquisition vertically from a mother who was symptomatic for a considerable period prior to birth [ 146 ]. The newborn delivered at 29 weeks gestational age and was already symptomatic with advanced respiratory disease and acidosis at delivery during caesarean section.…”

Section: Antenatal or Neonatal Infection With Sars-cov-2mentioning

confidence: 99%

See 1 more Smart Citation

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The maternal-fetal/newborn unit is established at risk for COVID-19 infection. This narrative review summarizes the contemporary and cumulative publications which detail maternal infection, antenatal and newborn infections, and maternal/fetal/newborn management and prevention. There is a wide spectrum of maternal disease, but the potential for severe disease albeit in a minority is confirmed. COVID-19 carries risk for preterm delivery. Pregnant females can suffer multisystem disease, and co-morbidities play a significant role in risk. Congenital infection has been supported by several anecdotal reports, but strong confirmatory data are few. No typical congenital dysmorphisms are evident. Nevertheless, placental vascular compromise must be considered a risk for the fetus during advanced maternal infections. Clinical manifestations of newborn infection have been mild to moderate and relatively uncommon. Proven antiviral therapy is of yet lacking. The mode of delivery is a medical decision that must include patient risk assessment and patient directives. Both presymptomatic and asymptomatic mothers and offspring can complicate infection control management with the potential for spread to others in several regards. In the interim, infections of the maternal-fetal-newborn unit must be taken seriously both for the disease so caused and the potential for further dissemination of disease.

show abstract

Section: Maternal Infection With Sars-cov-2supporting

confidence: 89%

Section: Antenatal or Neonatal Infection With Sars-cov-2mentioning

confidence: 99%

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…In one study, anti-SARS-CoV-2 IgM was detected at birth in two out of six newborns of women infected with SARS-CoV-2 during pregnancy ( 42 ), and in a 2-hour old newborn ( 43 ). In addition, anti-SARS-CoV-2 IgM was detected in one out of 31 cord blood samples of women infected with SARS-CoV-2 within 1-17 days prior to delivery ( 44 ), and in a 29-week preterm infant ( 45 ). Among 65 women with positive SARS-CoV-2 PCR detected during various stages in pregnancy (10-38 weeks), five neonates had anti-SARS-CoV-2 IgM in cord blood, with none of the newborns exhibiting signs of COVID-19 ( 34 ).…”

Section: Transfer Of Anti-sars-cov-2 Antibodies Following Infection In Pregnancymentioning

confidence: 99%

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease 2019 (COVID-19) vaccines in pregnant women; however, important knowledge gaps remain which warrant further studies. This collaborative consensus paper provides a review of the current literature on COVID-19 vaccines in pregnant women, identifies knowledge gaps and outlines priorities for future research to optimize protection against SARS-CoV-2 in the pregnant women and their infants.

show abstract

“…The MIA is readily adaptable to measuring responses of different Ig isotypes, different specimen matrices, and high throughput analyses. For example, our laboratory has used the MIA to detect IgM antibodies reactive with the SARS-CoV-2 N, RBD, and full-length spike in both newborn serum and adult CSF to suggest in situ infections ((24) and unpublished observations). However, isotype analyses may have their highest value in delineating the stage of infection.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay

Hunt

Yates

Kulas

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.

show abstract

In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant

Cited by 10 publications

References 18 publications

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay

Contact Info

Product

Resources

About